Back to search results

MyPath for Reproductive Planning in Postpartum Women with Substance Use Disorder

This study is testing a new tool called MyPath. MyPath is designed to help women with substance use disorders (SUDs) make decisions about contraception (birth control) after giving birth. The goal is to help women make choices that match their reproductive goals and avoid unintended pregnancies. Researchers want to see if using MyPath helps women continue using their chosen birth control method and use contraception consistently for up to 18 months after delivery. You may be able to join if you are a pregnant woman, 18 years or older, between 22 and 37 weeks pregnant, plan to deliver at the research site, and have a substance use disorder. The study is currently unclear about its recruitment status and plans to enroll 400 participants.

Study design
This is an interventional study comparing the MyPath tool to usual care. It plans to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from delivery up to 18 months post-delivery to track contraceptive use.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04939012

Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period

Recruiting
NAAges 18+InterventionalHealth services
University of Pittsburgh
~400 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:MyPath InterventionUsual care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Contraceptive method continuation
Measured over Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery
+1 more outcome measured

Conditions

Substance Use Disorders
Pregnancy Related
Contraception

Explore related trials

PregnancySubstance use disorder

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Elizabeth Krans, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Elizabeth Krans, MD
[email protected]
(412) 641-3532
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be greater than or equal to 18 years of age.
Be pregnant with an EGA of 22 to 37 weeks at enrollment.
Plan to deliver at research site.
Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.
Be greater than or equal to 18 years of age.
Be 0-9 days postpartum at enrollment.
Have delivered at research site.
Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.

Exclusion

Have had a fetal or neonatal death with their current pregnancy.
Be currently in jail or prison as required by court of law. Persons on probation or in residential facilities do not need to be excluded.
Have any other condition (social or medical) which, in the opinion of the Investigator, would make study participation unsafe, make study participation difficult, and/or complicate data interpretation.
PPC ONLY: Documented tubal ligation or hysterectomy procedures at time of delivery hospitalization

What this trial measures

  • Contraceptive method continuationDelivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

    Contraceptive method continuation as measured at each postpartum follow-up assessment by participants use of the same contraceptive method as she did at the previous timepoint.

  • Continuous contraceptive useDelivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

    Continuous contraceptive use as measured by participants continuously using any moderately (i.e., pill, patch, or ring, injection) or highly effective (i.e., long-acting reversible contraceptive (LARC), tubal ligation) method at consecutive timepoints. Reasons for stopping or switching methods will also be obtained.